Search

Your search keyword '"Brehler, Randolf"' showing total 1,356 results

Search Constraints

Start Over You searched for: Author "Brehler, Randolf" Remove constraint Author: "Brehler, Randolf"
1,356 results on '"Brehler, Randolf"'

Search Results

52. Correction to: Guideline for the diagnosis of drug hypersensitivity reactions

53. Beekeepers

55. Immunologisch relevante Aspekte der neuen COVID-19-Impfstoffe

56. Management of suspected and confirmedCOVID‐19 (SARS‐CoV‐2) vaccine hypersensitivity

58. Praktischer Umgang mit allergischen Reaktionen auf COVID-19-Impfstoffe

60. Schwere allergische Reaktionen nach COVID-19-Impfung mit dem Impfstoff von Pfizer/BioNTech in Großbritannien und USA

61. German S1 guideline: Contact dermatitis

62. S1‐Leitlinie Kontaktekzem

63. Guideline on allergen immunotherapy in IgE-mediated allergic diseases: S2K Guideline of the German Society of Allergology and Clinical Immunology (DGAKI), Society of Pediatric Allergology and Environmental Medicine (GPA), Medical Association of German Allergologists (AeDA), Austrian Society of Allergology and Immunology (ÖGAI), Swiss Society for Allergology and Immunology (SSAI), German Dermatological Society (DDG), German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), German Society of Pediatrics and Adolescent Medicine (DGKJ), Society of Pediatric Pulmonology (GPP), German Respiratory Society (DGP), German Professional Association of Otolaryngologists (BVHNO), German Association of Paediatric and Adolescent Care Specialists (BVKJ), Federal Association of Pneumologists, Sleep and Respiratory Physicians (BdP), Professional Association of German Dermatologists (BVDD)

64. Contact sensitization to essential oils: IVDK data of the years 2010–2019

65. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM)

66. Epidemiologie, Krankheitslast und gesundheitsökonomische Aspekte

68. Anwendung von Biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen Covid-19-Pandemiea, b, c

69. German S1 guideline: Contact dermatitis

70. White Paper Erdnussallergie - Teil 1: Epidemiologie, Burden of Disease, gesundheitsökonomische Aspekte

71. Management of suspected and confirmed COVID‐19 (SARS‐CoV‐2) vaccine hypersensitivity.

72. The European Curriculum for Additional Qualification Allergology A Position Paper by Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA) in cooperation with European Academy for Allergology and Clinical Immunology (EAACI) and Allergology Section of European Union of Medical Specialists (UEMS)

73. Contact dermatitis and sensitization in professional musicians

76. Das europäische Curriculum für die Zusatzbezeichnung Allergologie. Ein Positionspapier des Ärzteverbandes Deutscher Allergologen (AeDA)A, der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI)B und der Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)C in Kooperation mit der Europäischen Akademie für Allergologie und klinische Immunologie (EAACI)D und der Sektion Allergologie der Europäischen Union Medizinischer Spezialisten (UEMS)E

77. Das europäische Curriculum für die Zusatzbezeichnung Allergologie

78. Practical handling of allergic reactions to COVID-19 vaccines

79. Management von Anaphylaxie-gefährdeten Patienten während der Covid-19-Pandemie

83. COVID‐19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper

84. COVID-19 vaccination and allergen immunotherapy (AIT) - A position paper of the German Society for Applied Allergology (AeDA) and the German Society for Allergology and Clinical Immunology (DGAKI)

85. COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologicals) – A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society for Applied Allergo

86. Induction of penicillin tolerance during pregnancy: Allergological opinion on the recommendation of the current AWMF Guidelines on Diagnosis and Treatment of Syphilis (AWMF Registry No. 059-002)

87. Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA: Position paper of the German ARIA GroupA in cooperation with the Austrian ARIA GroupB, the Swiss ARIA GroupC, German Society for Applied Allergology (AEDA)D, German Society for Allergology and Clinical Immunology (DGAKI)E, Society for Pediatric Allergology (GPA)F in cooperation with AG Clinical Immunology, Allergology and Environmental Medicine of the DGHNO-KHCG and the European Academy of Allergy and Clinical Immunology (EAACI)H

88. Anwendung von Biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen Covid-19-Pandemie

89. Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic:Position paper of Ärzteverband Deutscher Allergologen (AeDA)A, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)B, Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)C, Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI)D, Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI)E, Österreichische Gesellschaft für Pneumologie (ÖGP)F in co-operation with the German, Austrian, and Swiss ARIA groupsG, and the European Academy of Allergy and Clinical Immunology (EAACI)

91. Versorgungssituation von Insektengiftallergikern während der COVID-19-Pandemie

94. Central Type of Neurofibromatosis

95. Alkalosis

96. Cardiomyopathies

97. Atrial Fibrillation

98. Cavernous Haemangioma

99. Cardiac Infarction

100. Cardiomyopathy, Dilated

Catalog

Books, media, physical & digital resources